NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Sunnyvale, California – November 18, 2024
Company reports record revenue of $1.7 million in Q3 Company announced a partnership in the high growth biopesticides sector that
Sunnyvale, California – November 7, 2024 – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company
Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development
The agreement with Kalsec anticipates milestone payments for finalizing research and development work and a royalty stream for Willow upon
Company reports record revenue of $1.0 million, an increase of approximately 600% over the second quarter of 2023 Signed strategic
Phone: +1 403 910 5140
Email: info@willowbio.com
© 2023 Willow Biosciences Inc.
Powered by BragDeal Inc.
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.